APO Research
Talk to an analyst

APO RESEARCH · REPORT

Peptide Antibiotics

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global Peptide Antibiotics Market Outlook and Growth Opportunities 2026

26 December 2025197 pages

Choose your research edition.

Industry ResearchPeptide Antibiotics Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Peptide Antibiotics Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal Peptide Antibiotics Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Peptide Antibiotics Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Peptide Antibiotics Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Peptide Antibiotics market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for Peptide Antibiotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Peptide Antibiotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Peptide Antibiotics is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the Peptide Antibiotics market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the Peptide Antibiotics market include AMP Therapeutics, Hospira, Kasten, Madam Therapeutics, Pacgen Life Science Corporation, Phosphagenics, Savara Pharmaceuticals, Theravance and Vicuron Pharmaceuticals, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Peptide Antibiotics market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Peptide Antibiotics and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Peptide Antibiotics sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Peptide Antibiotics market size, projected growth trends, production technologies, key applications, and end-use industries.

Peptide Antibiotics Segment by Company

AMP Therapeutics

Hospira

Kasten

Madam Therapeutics

Pacgen Life Science Corporation

Phosphagenics

Savara Pharmaceuticals

Theravance

Vicuron Pharmaceuticals

GlaxoSmithKline

Pfizer

Eli Lilly

Novartis

Peptide Antibiotics Segment by Type

Ribosomal Synthesized Peptide Antibiotics

Non-Ribosomally Synthesized Peptide Antibiotics

Peptide Antibiotics Segment by Application

Pharma & Healthcare

Food Industry

Commodities

Other

Peptide Antibiotics Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global Peptide Antibiotics status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions Peptide Antibiotics market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify Peptide Antibiotics significant trends, drivers, influence factors in global and regions.

6. To analyze Peptide Antibiotics competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Peptide Antibiotics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Peptide Antibiotics and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Peptide Antibiotics.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Peptide Antibiotics market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global Peptide Antibiotics industry.

Chapter 3: Detailed analysis of Peptide Antibiotics manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of Peptide Antibiotics in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of Peptide Antibiotics in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. Peptide Antibiotics Industry Trends Table 2. Peptide Antibiotics Industry Drivers Table 3. Peptide Antibiotics Industry Opportunities and Challenges Table 4. Peptide Antibiotics Industry Restraints Table 5. Global Peptide Antibiotics Revenue by Company (US$ Million) & (2021-2026) Table 6. Global Peptide Antibiotics Revenue Share by Company (2021-2026) Table 7. Global Peptide Antibiotics Sales Volume by Company (Tons) & (2021-2026) Table 8. Global Peptide Antibiotics Sales Volume Share by Company (2021-2026) Table 9. Global Peptide Antibiotics Average Price (US$/Ton) of Company (2021-2026) Table 10. Global Peptide Antibiotics Company Ranking, (2024-2026) & (USD Million) Table 11. Global Peptide Antibiotics Key Company Manufacturing Base & Headquarters Table 12. Global Peptide Antibiotics Company, Product Type & Application Table 13. Global Peptide Antibiotics Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global Peptide Antibiotics by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Ribosomal Synthesized Peptide Antibiotics Table 18. Significant Companies of Non-Ribosomally Synthesized Peptide Antibiotics Table 19. Global Peptide Antibiotics Sales Volume by Type 2021 VS 2025 VS 2032 (Tons) Table 20. Global Peptide Antibiotics Sales Volume by Type (2021-2026) & (Tons) Table 21. Global Peptide Antibiotics Sales Volume by Type (2027-2032) & (Tons) Table 22. Global Peptide Antibiotics Sales Volume Share by Type (2021-2026) Table 23. Global Peptide Antibiotics Sales Volume Share by Type (2027-2032) Table 24. Global Peptide Antibiotics Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global Peptide Antibiotics Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global Peptide Antibiotics Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global Peptide Antibiotics Sales Value Share by Type (2021-2026) Table 28. Global Peptide Antibiotics Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Pharma & Healthcare Table 30. Significant Companies of Food Industry Table 31. Significant Companies of Commodities Table 32. Significant Companies of Other Table 33. Global Peptide Antibiotics Sales Volume by Application 2021 VS 2025 VS 2032 (Tons) Table 34. Global Peptide Antibiotics Sales Volume by Application (2021-2026) & (Tons) Table 35. Global Peptide Antibiotics Sales Volume by Application (2027-2032) & (Tons) Table 36. Global Peptide Antibiotics Sales Volume Share by Application (2021-2026) Table 37. Global Peptide Antibiotics Sales Volume Share by Application (2027-2032) Table 38. Global Peptide Antibiotics Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 39. Global Peptide Antibiotics Sales Value by Application (2021-2026) & (US$ Million) Table 40. Global Peptide Antibiotics Sales Value by Application (2027-2032) & (US$ Million) Table 41. Global Peptide Antibiotics Sales Value Share by Application (2021-2026) Table 42. Global Peptide Antibiotics Sales Value Share by Application (2027-2032) Table 43. Global Peptide Antibiotics Sales by Region: 2021 VS 2025 VS 2032 (Tons) Table 44. Global Peptide Antibiotics Sales by Region (2021-2026) & (Tons) Table 45. Global Peptide Antibiotics Sales Market Share by Region (2021-2026) Table 46. Global Peptide Antibiotics Sales by Region (2027-2032) & (Tons) Table 47. Global Peptide Antibiotics Sales Market Share by Region (2027-2032) Table 48. Global Peptide Antibiotics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 49. Global Peptide Antibiotics Sales Value by Region (2021-2026) & (US$ Million) Table 50. Global Peptide Antibiotics Sales Value Share by Region (2021-2026) Table 51. Global Peptide Antibiotics Sales Value by Region (2027-2032) & (US$ Million) Table 52. Global Peptide Antibiotics Sales Value Share by Region (2027-2032) Table 53. Global Peptide Antibiotics Market Average Price (US$/Ton) by Region (2021-2026) Table 54. Global Peptide Antibiotics Market Average Price (US$/Ton) by Region (2027-2032) Table 55. Global Peptide Antibiotics Sales by Country: 2021 VS 2025 VS 2032 (Tons) Table 56. Global Peptide Antibiotics Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 57. Global Peptide Antibiotics Sales by Country (2021-2026) & (Tons) Table 58. Global Peptide Antibiotics Sales Market Share by Country (2021-2026) Table 59. Global Peptide Antibiotics Sales by Country (2027-2032) & (Tons) Table 60. Global Peptide Antibiotics Sales Market Share by Country (2027-2032) Table 61. Global Peptide Antibiotics Sales Value by Country (2021-2026) & (US$ Million) Table 62. Global Peptide Antibiotics Sales Value Market Share by Country (2021-2026) Table 63. Global Peptide Antibiotics Sales Value by Country (2027-2032) & (US$ Million) Table 64. Global Peptide Antibiotics Sales Value Market Share by Country (2027-2032) Table 65. AMP Therapeutics Company Information Table 66. AMP Therapeutics Business Overview Table 67. AMP Therapeutics Peptide Antibiotics Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 68. AMP Therapeutics Peptide Antibiotics Product Portfolio Table 69. AMP Therapeutics Recent Development Table 70. Hospira Company Information Table 71. Hospira Business Overview Table 72. Hospira Peptide Antibiotics Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 73. Hospira Peptide Antibiotics Product Portfolio Table 74. Hospira Recent Development Table 75. Kasten Company Information Table 76. Kasten Business Overview Table 77. Kasten Peptide Antibiotics Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 78. Kasten Peptide Antibiotics Product Portfolio Table 79. Kasten Recent Development Table 80. Madam Therapeutics Company Information Table 81. Madam Therapeutics Business Overview Table 82. Madam Therapeutics Peptide Antibiotics Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 83. Madam Therapeutics Peptide Antibiotics Product Portfolio Table 84. Madam Therapeutics Recent Development Table 85. Pacgen Life Science Corporation Company Information Table 86. Pacgen Life Science Corporation Business Overview Table 87. Pacgen Life Science Corporation Peptide Antibiotics Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 88. Pacgen Life Science Corporation Peptide Antibiotics Product Portfolio Table 89. Pacgen Life Science Corporation Recent Development Table 90. Phosphagenics Company Information Table 91. Phosphagenics Business Overview Table 92. Phosphagenics Peptide Antibiotics Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 93. Phosphagenics Peptide Antibiotics Product Portfolio Table 94. Phosphagenics Recent Development Table 95. Savara Pharmaceuticals Company Information Table 96. Savara Pharmaceuticals Business Overview Table 97. Savara Pharmaceuticals Peptide Antibiotics Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 98. Savara Pharmaceuticals Peptide Antibiotics Product Portfolio Table 99. Savara Pharmaceuticals Recent Development Table 100. Theravance Company Information Table 101. Theravance Business Overview Table 102. Theravance Peptide Antibiotics Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 103. Theravance Peptide Antibiotics Product Portfolio Table 104. Theravance Recent Development Table 105. Vicuron Pharmaceuticals Company Information Table 106. Vicuron Pharmaceuticals Business Overview Table 107. Vicuron Pharmaceuticals Peptide Antibiotics Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 108. Vicuron Pharmaceuticals Peptide Antibiotics Product Portfolio Table 109. Vicuron Pharmaceuticals Recent Development Table 110. GlaxoSmithKline Company Information Table 111. GlaxoSmithKline Business Overview Table 112. GlaxoSmithKline Peptide Antibiotics Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 113. GlaxoSmithKline Peptide Antibiotics Product Portfolio Table 114. GlaxoSmithKline Recent Development Table 115. Pfizer Company Information Table 116. Pfizer Business Overview Table 117. Pfizer Peptide Antibiotics Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 118. Pfizer Peptide Antibiotics Product Portfolio Table 119. Pfizer Recent Development Table 120. Eli Lilly Company Information Table 121. Eli Lilly Business Overview Table 122. Eli Lilly Peptide Antibiotics Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 123. Eli Lilly Peptide Antibiotics Product Portfolio Table 124. Eli Lilly Recent Development Table 125. Novartis Company Information Table 126. Novartis Business Overview Table 127. Novartis Peptide Antibiotics Sales (Tons), Value (US$ Million), Price (US$/Ton) and Gross Margin (2021-2026) Table 128. Novartis Peptide Antibiotics Product Portfolio Table 129. Novartis Recent Development Table 130. Key Raw Materials Table 131. Raw Materials Key Suppliers Table 132. Peptide Antibiotics Distributors List Table 133. Peptide Antibiotics Customers List Table 134. Research Programs/Design for This Report Table 135. Authors List of This Report Table 136. Secondary Sources Table 137. Primary Sources List of Figures Figure 1. Peptide Antibiotics Product Image Figure 2. Global Peptide Antibiotics Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Peptide Antibiotics Sales Value (2021-2032) & (US$ Million) Figure 4. Global Peptide Antibiotics Sales (2021-2032) & (Tons) Figure 5. Global Peptide Antibiotics Sales Average Price (US$/Ton) & (2021-2032) Figure 6. Global Peptide Antibiotics Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Ribosomal Synthesized Peptide Antibiotics Image Figure 10. Non-Ribosomally Synthesized Peptide Antibiotics Image Figure 11. Global Peptide Antibiotics Sales Volume by Type (2021 VS 2025 VS 2032) & (Tons) Figure 12. Global Peptide Antibiotics Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global Peptide Antibiotics Sales Volume Share by Type (2021-2032) Figure 14. Global Peptide Antibiotics Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global Peptide Antibiotics Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global Peptide Antibiotics Sales Value Share by Type (2021-2032) Figure 17. Pharma & Healthcare Image Figure 18. Food Industry Image Figure 19. Commodities Image Figure 20. Other Image Figure 21. Global Peptide Antibiotics Sales Volume by Application (2021 VS 2025 VS 2032) & (Tons) Figure 22. Global Peptide Antibiotics Sales Volume Share 2021 VS 2025 VS 2032 Figure 23. Global Peptide Antibiotics Sales Volume Share by Application (2021-2032) Figure 24. Global Peptide Antibiotics Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 25. Global Peptide Antibiotics Sales Value Share 2021 VS 2025 VS 2032 Figure 26. Global Peptide Antibiotics Sales Value Share by Application (2021-2032) Figure 27. Global Peptide Antibiotics Sales by Region: 2021 VS 2025 VS 2032 (Tons) Figure 28. Global Peptide Antibiotics Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 29. Global Peptide Antibiotics Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 30. Global Peptide Antibiotics Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 31. North America Peptide Antibiotics Sales Value (2021-2032) & (US$ Million) Figure 32. North America Peptide Antibiotics Sales Value Share by Country (%), 2025 VS 2032 Figure 33. Europe Peptide Antibiotics Sales Value (2021-2032) & (US$ Million) Figure 34. Europe Peptide Antibiotics Sales Value Share by Country (%), 2025 VS 2032 Figure 35. Asia-Pacific Peptide Antibiotics Sales Value (2021-2032) & (US$ Million) Figure 36. Asia-Pacific Peptide Antibiotics Sales Value Share by Country (%), 2025 VS 2032 Figure 37. South America Peptide Antibiotics Sales Value (2021-2032) & (US$ Million) Figure 38. South America Peptide Antibiotics Sales Value Share by Country (%), 2025 VS 2032 Figure 39. Middle East & Africa Peptide Antibiotics Sales Value (2021-2032) & (US$ Million) Figure 40. Middle East & Africa Peptide Antibiotics Sales Value Share by Country (%), 2025 VS 2032 Figure 41. USA Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 42. USA Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 43. USA Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 44. Canada Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 45. Canada Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 46. Canada Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 47. Mexico Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 48. Mexico Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 49. Mexico Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 50. Germany Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 51. Germany Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 52. Germany Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 53. France Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 54. France Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 55. France Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 56. U.K. Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 57. U.K. Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 58. U.K. Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 59. Italy Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 60. Italy Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 61. Italy Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 62. Spain Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 63. Spain Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 64. Spain Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 65. Russia Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 66. Russia Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 67. Russia Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 68. Netherlands Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 69. Netherlands Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 70. Netherlands Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 71. Nordic Countries Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 72. Nordic Countries Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 73. Nordic Countries Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 74. China Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 75. China Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 76. China Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 77. Japan Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 78. Japan Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 79. Japan Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 80. South Korea Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 81. South Korea Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 82. South Korea Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 83. India Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 84. India Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 85. India Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 86. Australia Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 87. Australia Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 88. Australia Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 89. Southeast Asia Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 90. Southeast Asia Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 91. Southeast Asia Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 92. Brazil Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 93. Brazil Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 94. Brazil Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 95. Argentina Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 96. Argentina Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 97. Argentina Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 98. Chile Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 99. Chile Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 100. Chile Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 101. Colombia Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 102. Colombia Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 103. Colombia Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 104. Peru Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 105. Peru Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 106. Peru Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 107. Saudi Arabia Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 108. Saudi Arabia Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 109. Saudi Arabia Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 110. Israel Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 111. Israel Arabia Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 112. Israel Arabia Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 113. UAE Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 114. UAE Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 115. UAE Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 116. Turkey Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 117. Turkey Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 118. Turkey Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 119. Iran Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 120. Iran Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 121. Iran Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 122. Egypt Peptide Antibiotics Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 123. Egypt Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032 & (%) Figure 124. Egypt Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032 & (%) Figure 125. Peptide Antibiotics Value Chain Figure 126. Manufacturing Cost Structure Figure 127. Peptide Antibiotics Sales Mode & Process Figure 128. Direct Comparison with Distribution Share Figure 129. Distributors Profiles Figure 130. Years Considered Figure 131. Research Process Figure 132. Key Executives Interviewed

Scope & coverage.

Types
  • Ribosomal Synthesized Peptide Antibiotics
  • Non-Ribosomally Synthesized Peptide Antibiotics
Applications
  • Pharma & Healthcare
  • Food Industry
  • Commodities
  • Other
Companies covered
  • AMP Therapeutics
  • Hospira
  • Kasten
  • Madam Therapeutics
  • Pacgen Life Science Corporation
  • Phosphagenics
  • Savara Pharmaceuticals
  • Theravance
  • Vicuron Pharmaceuticals
  • GlaxoSmithKline
  • Pfizer
  • Eli Lilly
  • Novartis

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global Peptide Antibiotics Sales Value (2021-2032)
  4. 1.2.2 Global Peptide Antibiotics Sales Volume (2021-2032)
  5. 1.2.3 Global Peptide Antibiotics Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 Peptide Antibiotics Market Dynamics
  1. 2.1 Peptide Antibiotics Industry Trends
  2. 2.2 Peptide Antibiotics Industry Drivers
  3. 2.3 Peptide Antibiotics Industry Opportunities and Challenges
  4. 2.4 Peptide Antibiotics Industry Restraints
3 Peptide Antibiotics Market by Company
  1. 3.1 Global Peptide Antibiotics Company Revenue Ranking in 2025
  2. 3.2 Global Peptide Antibiotics Revenue by Company (2021-2026)
  3. 3.3 Global Peptide Antibiotics Sales Volume by Company (2021-2026)
  4. 3.4 Global Peptide Antibiotics Average Price by Company (2021-2026)
  5. 3.5 Global Peptide Antibiotics Company Ranking (2024-2026)
  6. 3.6 Global Peptide Antibiotics Company Manufacturing Base and Headquarters
  7. 3.7 Global Peptide Antibiotics Company Product Type and Application
  8. 3.8 Global Peptide Antibiotics Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global Peptide Antibiotics Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 Peptide Antibiotics Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 Peptide Antibiotics Market by Type
  1. 4.1 Peptide Antibiotics Type Introduction
  2. 4.1.1 Ribosomal Synthesized Peptide Antibiotics
  3. 4.1.2 Non-Ribosomally Synthesized Peptide Antibiotics
  4. 4.2 Global Peptide Antibiotics Sales Volume by Type
  5. 4.2.1 Global Peptide Antibiotics Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global Peptide Antibiotics Sales Volume by Type (2021-2032)
  7. 4.2.3 Global Peptide Antibiotics Sales Volume Share by Type (2021-2032)
  8. 4.3 Global Peptide Antibiotics Sales Value by Type
  9. 4.3.1 Global Peptide Antibiotics Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global Peptide Antibiotics Sales Value by Type (2021-2032)
  11. 4.3.3 Global Peptide Antibiotics Sales Value Share by Type (2021-2032)
5 Peptide Antibiotics Market by Application
  1. 5.1 Peptide Antibiotics Application Introduction
  2. 5.1.1 Pharma & Healthcare
  3. 5.1.2 Food Industry
  4. 5.1.3 Commodities
  5. 5.1.4 Other
  6. 5.2 Global Peptide Antibiotics Sales Volume by Application
  7. 5.2.1 Global Peptide Antibiotics Sales Volume by Application (2021 VS 2025 VS 2032)
  8. 5.2.2 Global Peptide Antibiotics Sales Volume by Application (2021-2032)
  9. 5.2.3 Global Peptide Antibiotics Sales Volume Share by Application (2021-2032)
  10. 5.3 Global Peptide Antibiotics Sales Value by Application
  11. 5.3.1 Global Peptide Antibiotics Sales Value by Application (2021 VS 2025 VS 2032)
  12. 5.3.2 Global Peptide Antibiotics Sales Value by Application (2021-2032)
  13. 5.3.3 Global Peptide Antibiotics Sales Value Share by Application (2021-2032)
6 Peptide Antibiotics Regional Sales and Value Analysis
  1. 6.1 Global Peptide Antibiotics Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Peptide Antibiotics Sales by Region (2021-2032)
  3. 6.2.1 Global Peptide Antibiotics Sales by Region: 2021-2026
  4. 6.2.2 Global Peptide Antibiotics Sales by Region (2027-2032)
  5. 6.3 Global Peptide Antibiotics Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global Peptide Antibiotics Sales Value by Region (2021-2032)
  7. 6.4.1 Global Peptide Antibiotics Sales Value by Region: 2021-2026
  8. 6.4.2 Global Peptide Antibiotics Sales Value by Region (2027-2032)
  9. 6.5 Global Peptide Antibiotics Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America Peptide Antibiotics Sales Value (2021-2032)
  12. 6.6.2 North America Peptide Antibiotics Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe Peptide Antibiotics Sales Value (2021-2032)
  15. 6.7.2 Europe Peptide Antibiotics Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific Peptide Antibiotics Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific Peptide Antibiotics Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America Peptide Antibiotics Sales Value (2021-2032)
  21. 6.9.2 South America Peptide Antibiotics Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa Peptide Antibiotics Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa Peptide Antibiotics Sales Value Share by Country, 2025 VS 2032
7 Peptide Antibiotics Country-level Sales and Value Analysis
  1. 7.1 Global Peptide Antibiotics Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global Peptide Antibiotics Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global Peptide Antibiotics Sales by Country (2021-2032)
  4. 7.3.1 Global Peptide Antibiotics Sales by Country (2021-2026)
  5. 7.3.2 Global Peptide Antibiotics Sales by Country (2027-2032)
  6. 7.4 Global Peptide Antibiotics Sales Value by Country (2021-2032)
  7. 7.4.1 Global Peptide Antibiotics Sales Value by Country (2021-2026)
  8. 7.4.2 Global Peptide Antibiotics Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt Peptide Antibiotics Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt Peptide Antibiotics Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt Peptide Antibiotics Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 AMP Therapeutics
  2. 8.1.1 AMP Therapeutics Company Information
  3. 8.1.2 AMP Therapeutics Business Overview
  4. 8.1.3 AMP Therapeutics Peptide Antibiotics Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 AMP Therapeutics Peptide Antibiotics Product Portfolio
  6. 8.1.5 AMP Therapeutics Recent Developments
  7. 8.2 Hospira
  8. 8.2.1 Hospira Company Information
  9. 8.2.2 Hospira Business Overview
  10. 8.2.3 Hospira Peptide Antibiotics Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Hospira Peptide Antibiotics Product Portfolio
  12. 8.2.5 Hospira Recent Developments
  13. 8.3 Kasten
  14. 8.3.1 Kasten Company Information
  15. 8.3.2 Kasten Business Overview
  16. 8.3.3 Kasten Peptide Antibiotics Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Kasten Peptide Antibiotics Product Portfolio
  18. 8.3.5 Kasten Recent Developments
  19. 8.4 Madam Therapeutics
  20. 8.4.1 Madam Therapeutics Company Information
  21. 8.4.2 Madam Therapeutics Business Overview
  22. 8.4.3 Madam Therapeutics Peptide Antibiotics Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Madam Therapeutics Peptide Antibiotics Product Portfolio
  24. 8.4.5 Madam Therapeutics Recent Developments
  25. 8.5 Pacgen Life Science Corporation
  26. 8.5.1 Pacgen Life Science Corporation Company Information
  27. 8.5.2 Pacgen Life Science Corporation Business Overview
  28. 8.5.3 Pacgen Life Science Corporation Peptide Antibiotics Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Pacgen Life Science Corporation Peptide Antibiotics Product Portfolio
  30. 8.5.5 Pacgen Life Science Corporation Recent Developments
  31. 8.6 Phosphagenics
  32. 8.6.1 Phosphagenics Company Information
  33. 8.6.2 Phosphagenics Business Overview
  34. 8.6.3 Phosphagenics Peptide Antibiotics Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Phosphagenics Peptide Antibiotics Product Portfolio
  36. 8.6.5 Phosphagenics Recent Developments
  37. 8.7 Savara Pharmaceuticals
  38. 8.7.1 Savara Pharmaceuticals Company Information
  39. 8.7.2 Savara Pharmaceuticals Business Overview
  40. 8.7.3 Savara Pharmaceuticals Peptide Antibiotics Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 Savara Pharmaceuticals Peptide Antibiotics Product Portfolio
  42. 8.7.5 Savara Pharmaceuticals Recent Developments
  43. 8.8 Theravance
  44. 8.8.1 Theravance Company Information
  45. 8.8.2 Theravance Business Overview
  46. 8.8.3 Theravance Peptide Antibiotics Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Theravance Peptide Antibiotics Product Portfolio
  48. 8.8.5 Theravance Recent Developments
  49. 8.9 Vicuron Pharmaceuticals
  50. 8.9.1 Vicuron Pharmaceuticals Company Information
  51. 8.9.2 Vicuron Pharmaceuticals Business Overview
  52. 8.9.3 Vicuron Pharmaceuticals Peptide Antibiotics Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 Vicuron Pharmaceuticals Peptide Antibiotics Product Portfolio
  54. 8.9.5 Vicuron Pharmaceuticals Recent Developments
  55. 8.10 GlaxoSmithKline
  56. 8.10.1 GlaxoSmithKline Company Information
  57. 8.10.2 GlaxoSmithKline Business Overview
  58. 8.10.3 GlaxoSmithKline Peptide Antibiotics Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 GlaxoSmithKline Peptide Antibiotics Product Portfolio
  60. 8.10.5 GlaxoSmithKline Recent Developments
  61. 8.11 Pfizer
  62. 8.11.1 Pfizer Company Information
  63. 8.11.2 Pfizer Business Overview
  64. 8.11.3 Pfizer Peptide Antibiotics Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Pfizer Peptide Antibiotics Product Portfolio
  66. 8.11.5 Pfizer Recent Developments
  67. 8.12 Eli Lilly
  68. 8.12.1 Eli Lilly Company Information
  69. 8.12.2 Eli Lilly Business Overview
  70. 8.12.3 Eli Lilly Peptide Antibiotics Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Eli Lilly Peptide Antibiotics Product Portfolio
  72. 8.12.5 Eli Lilly Recent Developments
  73. 8.13 Novartis
  74. 8.13.1 Novartis Company Information
  75. 8.13.2 Novartis Business Overview
  76. 8.13.3 Novartis Peptide Antibiotics Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Novartis Peptide Antibiotics Product Portfolio
  78. 8.13.5 Novartis Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Peptide Antibiotics Value Chain Analysis
  2. 9.1.1 Peptide Antibiotics Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Peptide Antibiotics Sales Mode & Process
  6. 9.2 Peptide Antibiotics Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Peptide Antibiotics Distributors
  9. 9.2.3 Peptide Antibiotics Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst